Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

Marianne Pavel, David J. Gross, Marta Benavent, +15

Endocrine Related Cancer

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

Barbara Nuñez-Valdovinos, Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, +18

The Oncologist

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

Rodrigo Dienstmann, Amita Patnaik, Rocio García‐Carbonero, +16

Cancer Discovery

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

Sonia Molina‐Pinelo, Amancio Carnero, Fernando Rivera, +14

BMC Cancer

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Ángela Lamarca, +26

Journal of Clinical Oncology

Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

Cédric Nesti, Konstantin Bräutigam, Marta Benavent, +71

The Lancet Oncology

Neuro-oncologyEndocrine OncologySurgical OncologyHemicolectomy Versus AppendectomySurgical Pathology +4

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer

Mónica Cejuela Solís, Ana Gil-Torralvo, María Ángeles Castilla, +6

International Journal of Molecular Sciences

Breast OncologyDirect ComparisonReal-world DataGynecologyFirst-line Treatment +18

1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

Jaume Capdevila, Àlex Teulé, Carlos López, +17

Annals of Oncology

Lung OriginEndocrine OncologyGetne 1601MedicineNeuroendocrine Disorder +6

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

Jaume Capdevila, Jorge Hernando, Àlex Teulé, +20

Nature Communications

The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)

Enrique Grande, Àlex Teulé, Teresa Alonso‐Gordoa, +15

The Oncologist